Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Main Article Content

AB Gottlieb
A Blauvelt
D Thaçi
Y Poulin
F Brock
C Arendt
M Boehnlein
K Reich

Keywords

Psoriasis, Plaque Psoriasis, Biologic, Tumor Necrosis Factor α, TNF α, Certolizumab Pegol

Abstract

Abstract not available.

References

1. Parisi R. J Invest Dermatol 2013;133:377–85

2. Gottlieb AB. JAAD 2018;79:302–14

3. Lebwohl M. JAAD 2018;79:266–76

4. Zweegers J. et al. Br J Dermatol 2017;176:786–93

5. Carrascosa Carrillo JM. J Dermatolog Treat 2017;29:140–4

6. Puig L. Eur J Dermatol 2015;25:410–7.